▶️ Unknown to many, the UK has enacted a legislation which could change the future of #precision and #personalised medicine.

Imagine losing your #sight—and no one knows why. 👁️👁️ Today is #CoatsDiseaseAwarenessDay, a day to learn the symptoms of #CoatsDisease and get to know Jack McGovern Coats' Disease Foundation, a NORD Member nonprofit whose mission is to save sight and change lives. Learn more: coatsdiseasefoundation.org Every

In response to considerable community interest, we have significantly updated our CCDC146 manuscript. medrxiv.org/content/10.110…

🧬 LIQUIK study. In metastatic #NSCLC, LiquidHALLMARK (ctDNA+ctRNA) improved biomarker detection vs ctDNA alone: 🔹 +28.6% gene rearrangements 🔹 +15.6% actionable biomarkers Tissue NGS remains gold standard, but ctRNA enhances liquid biopsy yield. JCO Precision Oncology 👉

Delighted to share our Cancer Cell paper published today, co-authored by Dr. Alexander Biederstädt Alexander Biederstädt, MD and Dr. Rafet Basar Rafet reporting the first genome-wide CRISPR screen in primary cord blood NK and CAR NK cells. We identify key genetic checkpoints including

NEW WEBINAR! On 9/10, our industry experts will discuss the impactful role of circulating tumor DNA (ctDNA) testing for MRD assessment in GI cancer management. Register now to join us for this free webinar sponsored by Natera: hubs.li/Q03DL9vj0

Most genetic reports label variants as ✅ “pathogenic” or ❌ “benign.” But what patients really want to know is: what are my chances of getting the disease? 🚨 In our new Science study, we used AI + 1.3M patient records to better answer that…

Multi pathway therapy reaching a new level with arrival of bispecific antibodies in NSCLC #Ivonescimab Vegf and PD1 inhibitor! Sandip Patel MD FASCO Prof Myung Ju Ahn Zosia Piotrowska Giannis Mountzios IASLC #WCLC25

Bioactive molecules unearthed by terabase-scale long-read sequencing of a soil metagenome go.nature.com/4606ozA

Proud to share our first TRACERx cancer study integrating epigenomics + genomics in NSCLC as co-drivers of tumor evolution. Led by not me but by the wonderful Nnennaya Kanu, Francisco Gimeno-Valiente, Carla Castignani, Peter Van Loo

Introducing our next series on #IntracellularCommunication, to explore how cells talk within. Our first feature is of IA Intermediate Fellow Dr. Rajender Motiani, studying ER-mitochondria crosstalk in skin pigmentation and melanophagy. Read more: tinyurl.com/bd5hhj98

Many thanks to DBT/WT India Alliance for featuring the work of our lab! Our sincere gratitude to DBT/WT India Alliance for supporting our research program and for being “the wind beneath our wings”!! Their flexible funding support has played a crucial role in our progress. 1/2

#ScienceSaturday ❓ Why do T cells sometimes fail to fight cancer? ➡️ A new study in Nature shows that when T cells are exposed to cancer or long-term infections, they can enter a state called exhaustion, where they lose their ability to eliminate harmful cells. ➡️ The

It was a honor to represent the nation & give an #Invited EMBO #Global #Investigator #Lecture at EMBO workshop on Membrane contact sites at Puglia, Italy. RCB Department of Biotechnology DBT/WT India Alliance Jyoti Tanwar KritiAhuja Anusandhan National Research Foundation ICMR linkedin.com/posts/rajender…

This is an incredible opportunity from Cancer Research Institute for postdoctoral fellows transitioning to early career faculty: cancerresearch.org/blog/ignite cancerresearch.org/IGNITE

Read a collection of articles from The Innovation: a Cell Press partner journal on advances in cancer diagnostics and precision therapies. hubs.li/Q03LG1Cd0

Serial multiomics reveals therapeutic effects of an anti-glioblastoma drug not picked up by routine clinical MRI analysis #NBThighlight science.org/doi/10.1126/sc…

New preprint! We know cancer cells with somatic mutations are selected to evade the immune system. With Inigo Martincorena Peter Campbell ZJL Quotient Therapeutics, we asked if immune cells with somatic mutations are also selected to fight cancer. biorxiv.org/content/10.110… 1/5

🚨 Humbled to share that I have reached a key milestone in my scientific journey, 50 publications on PubMed!🙏 Motivated to do even better! As they say its not about numbers its about quality of work; gratifying to see my contributions in several top notch journals! LinkedIn

Congrats to my postdoc, Aya Ludin Tal, on her Cell paper. Her work using live imaging in zebrafish identifies CRATERS on the surface of melanoma - immune hubs for T cells. CRATERS in human melanoma are the best predictors of immunotherapy success. authors.elsevier.com/sd/article/S00…